Array CGH improves detection of mutations in the GALC gene associated with Krabbe disease

Orphanet Journal of Rare Diseases

Madhuri Hegde²  Patricia K Duffner¹  Ephrem L H Chin²  Alice K Tanner² 

[1] Hunter James Kelly Research Institute, Department of Neurology, School of Medicine, State University of New York at Buffalo, Buffalo, NY, USA;Emory Genetics Laboratory, Department of Human Genetics, Emory University, Atlanta, GA, USA

关键词: Array CGH;    Duplication;    Deletion;    GALC;    Krabbe disease;   

Others  :  864353
DOI  :  10.1186/1750-1172-7-38

 received in 2012-01-17, accepted in 2012-06-15,  发布年份 2012

【 摘 要 】

Background

Krabbe disease is an autosomal recessive lysosomal storage disorder caused by mutations in the GALC gene. The most common mutation in the Caucasian population is a 30-kb deletion of exons 11 through 17. There are few other reports of intragenic GALC deletions or duplications, due in part to difficulties detecting them.

Methods and results

We used gene-targeted array comparative genomic hybridization (CGH) to analyze the GALC gene in individuals with Krabbe disease in whom sequence analysis with 30-kb deletion analysis identified only one mutation. In our sample of 33 cases, traditional approaches failed to identify two pathogenic mutations in five (15.2%) individuals with confirmed Krabbe disease. The addition of array CGH deletion/duplication analysis to the genetic testing strategy led to the identification of a second pathogenic mutation in three (9.1%) of these five individuals. In all three cases, the deletion or duplication identified through array CGH was a novel GALC mutation, including the only reported duplication in the GALC gene, which would have been missed by traditional testing methodologies. We report these three cases in detail. The second mutation remains unknown in the remaining two individuals (6.1%), despite our full battery of testing.

Conclusions

Analysis of the GALC gene using array CGH deletion/duplication testing increased the two-mutation detection rate from 84.8% to 93.9% in affected individuals. Better mutation detection rates are important for improving molecular diagnosis of Krabbe disease, as well as for providing prenatal and carrier testing in family members.

【 授权许可】

   
2012 Tanner et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Wenger DA, Rafi MA, Luzi P, Datto J, Costantino-Ceccarini E: Krabbe disease: genetic aspects and progress toward therapy. Mol Genet Metab 2000, 70:1-9.
• [2]Suzuki K, Suzuki Y: Globoid Cell Leukodystrophy (Krabbe's Disease): Deficiency of Galactocerebroside beta-Galactosidase. Proc Natl Acad Sci 1970, 66:302-309.
• [3]Wenger DA, Rafi MA, Luzi P: Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications. Hum Mutat 1997, 10:268-279.
• [4]Kemper AR, Knapp AA, Green NS, Comeau AM, Metterville DR, Perrin JM: Weighing the evidence for newborn screening for early-infantile Krabbe disease. Genet Med 2010, 12:539-543.
• [5]Wenger DA: Krabbe disease online NIH gene review. 2011. Available at http://wwwncbinlmnihgov/books/NBK1238/Accessed webcite February 25
• [6]Korn-Lubetzki I, Nevo Y: Infantile Krabbe disease. Arch Neurol 2003, 60:1643-1644.
• [7]Chen YQ, Rafi MA, de Gala G, Wenger DA: Cloning and expression of cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy. Hum Mol Genet 1993, 2:1841-1845.
• [8]Luzi P, Rafi MA, Wenger DA: Characterization of the large deletion in the GALC gene found in patients with Krabbe disease. Hum Mol Genet 1995, 4:2335-2338.
• [9]Rafi MA, Luzi P, Chen YQ, Wenger DA: A large deletion together with a point mutation in the GALC gene is a common mutant allele in patients with infantile Krabbe disease. Hum Mol Genet 1995, 4:1285-1289.
• [10]Duffner PK, Barczykowski A, Jalal K, Yan L, Kay DM, Carter RL: Early infantile Krabbe disease: results of the World-Wide Krabbe Registry. Pediatr Neurol 2011, 45:141-148.
• [11]Tayeh MK, Chin EL, Miller VR, Bean LJ, Coffee B, Hegde M: Targeted comparative genomic hybridization array for the detection of single- and multiexon gene deletions and duplications. Genet Med 2009, 11:232-240.
• [12]Aradhya S, Lewis R, Bonaga T, Nwokekeh N, Stafford A, Boggs B, Hruska K, Smaoui N, Compton JG, Richard G, Suchy S: Exon-level array CGH in a large clinical cohort demonstrates increased sensitivity of diagnostic testing for Mendelian disorders. Genet Med 2012, 14:594-603.
• [13]Wang J, Zhan H, Li FY, Pursley AN, Schmitt ES, Wong LJ: Targeted array CGH as a valuable molecular diagnostic approach: Experience in the diagnosis of mitochondrial and metabolic disorders. Mol Genet Metab 2012, 106:221-230.
• [14]Hegde MR, Chin EL, Mulle JG, Okou DT, Warren ST, Zwick ME: Microarray-based mutation detection in the dystrophin gene. Hum Mutat 2008, 29:1091-1099.